ABVX.PA AI Price Prediction

Track ABVX.PA's AI-powered predictions, market trends, and investment insights.

ABVX.PA Sentiment ABVX.PA StockTwits ABVX.PA Reddit

Mock Tradesimulated, no real money

You don't hold ABVX.PA in your mock portfolio yet.

ABVX.PA AI Price Prediction

Track ABVX.PA's AI-powered predictions, market trends, and investment insights.

ABVX.PA Sentiment ABVX.PA StockTwits ABVX.PA Reddit

Evidence Stack

What Changed?

Key moves vs recent baseline (last day / last week)

Price (1d)-0.1%

Price (7d)-3.2%

Volume vs avg0.2x

Volatility vs normal0.3x

Why Now?

Plain-English summary of the biggest drivers (informational)

Risk Flags

Potential risk factors to review

No flags triggered by these checks.

Based on earnings timing, volatility, liquidity and crowd activity. Informational signals only — not investment advice.

Invalidation Signals

Reassess your thesis if any of these occur:

Price breaks below ~€71.25 (recent support level)

Upgrade to see the full Evidence Stack

What Changed, Why Now, and Risk Flags — available on the Investor plan and above

Get Started

ABVX.PA AI Stock Analysis

Financial Performance

bearish

ABIVAX is currently loss-making, as indicated by its negative EPS and PE ratio. The lack of profitability suggests the company is still in an investment or clinical development phase rather than a mature, cash-generative stage. Until there is a clear path to positive earnings, the financial profile remains fundamentally high-risk.

Negative EPS of -4.61 indicates the company is not yet profitable and is likely consuming cash rather than generating it.
A PE ratio of -24.38 reflects that the market is valuing the stock on expectations of future success rather than current earnings.
Absence of positive earnings or profitability ratios implies continued dependence on external financing (equity or debt) and execution risk on the company’s pipeline or strategy.

Stock Price & Technicals

bullish

The stock has shown strong recent momentum, rising 16.5% over the last month and trading well above its 200-day moving average. This positioning suggests a positive medium-term trend and improving investor sentiment. However, the move is driven more by expectations than by current earnings strength.

Current price of €112.40 is meaningfully above the 200-day moving average of €94.59, a classically bullish technical signal indicating an established uptrend.
A 16.5% gain over the past month points to strong short-term momentum and growing investor interest.
With no RSI provided, the available technicals still lean positive, but the sharp recent rise raises the possibility of near-term volatility or profit-taking if expectations are not met.

Alternative Data Signals

neutral

Alternative data for ABIVAX is modest and relatively stable, without clear signs of either accelerating commercial traction or major deterioration. Web traffic and social media followings are small but present, and hiring activity is flat. These signals neither strongly confirm nor contradict the recent bullish price action.

Estimated monthly web traffic of 21,276 visitors is modest, suggesting limited broad-based retail or customer engagement at this stage, which is typical for an early-stage or R&D-focused biotech.
Zero current job openings and 0.0% month-over-month change indicate no visible hiring ramp, implying stable but not rapidly expanding operational activity.
Social media presence is small but slowly growing: 1,546 Twitter/X followers (up 1.3% over 90 days) and 18,271 LinkedIn followers, signaling some interest from professionals and investors but no explosive awareness spike.

Conclusion

neutral

ABIVAX’s stock shows bullish technical momentum but rests on a fundamentally loss-making base with limited alternative data support for a major commercial inflection. The setup looks like a typical high-risk, high-reward biotech profile where sentiment and expectations drive the share price more than current financials. Overall, the balance of strong price action against weak profitability and only moderate alternative signals leads to a neutral stance.

Bullish price trend and a level well above the 200-day moving average indicate strong current market optimism.
Negative earnings and limited alternative data traction temper that optimism, leaving the risk/reward profile highly dependent on future execution and catalysts rather than present fundamentals.

AI Score

Buy

Alternative8

Fundamental6

Technical7

Our AI Score rates companies on a scale from 0 to 10, based on alternative data points such as web traffic, app downloads, and job postings — combined with financial health indicators and technical signals.

Mock Tradesimulated, no real money

You don't hold ABVX.PA in your mock portfolio yet.